Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors

BACKGROUND: Clinical practice guidelines recommend sodium-glucose co-transporter 2 inhibitors (SGLT2is) to mitigate adverse kidney and cardiovascular outcomes in patients with type 2 diabetes (T2D), including patients with comorbid chronic kidney disease (CKD), also referred to as diabetic kidney di...

Descripción completa

Detalles Bibliográficos
Autores principales: Kovesdy, Csaba, Schmedt, Niklas, Folkerts, Kerstin, Bowrin, Kevin, Raad, Hanaya, Batech, Michael, Fried, Linda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744296/
https://www.ncbi.nlm.nih.gov/pubmed/35000594
http://dx.doi.org/10.1186/s12916-021-02191-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744296/
https://www.ncbi.nlm.nih.gov/pubmed/35000594
http://dx.doi.org/10.1186/s12916-021-02191-2

Ejemplares similares